Astec LifeSciences · NSE: ASTEC · BSE: 533138
Q1 FY23 results · Apr–Jun 2022
Astec LifeSciences reported revenue from operations of ₹184.27 crore (up 43.2% from Q1 FY22) and net profit of ₹11.41 crore (down 12.2% from Q1 FY22) for Q1 FY23 (Apr–Jun 2022), on a consolidated basis.
| Item | Q1 FY23 | Q1 FY22 | YoY | Q4 FY22 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 184.27 | 128.66 | +43.2% | 271.98 | −32.3% |
| Other income | 2.71 | 0.80 | +237.2% | 6.80 | −60.2% |
| Total income | 186.98 | 129.46 | +44.4% | 278.79 | −32.9% |
| Profit before tax | 15.31 | 17.44 | −12.2% | 58.30 | −73.7% |
| Net profit for the period | 11.41 | 12.99 | −12.2% | 43.06 | −73.5% |
| Attributable to shareholders of the company | 11.40 | 12.98 | −12.2% | 43.05 | −73.5% |
| EPS, basic (₹) | 5.82 | 6.63 | −12.2% | 21.97 | −73.5% |
| Net margin (%) | 6.2 | 10.1 | 15.8 |
| Item | Q1 FY23 | Q1 FY22 | YoY | Q4 FY22 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 184.27 | 128.66 | +43.2% | 271.98 | −32.3% |
| Other income | 2.71 | 0.80 | +236.7% | 6.80 | −60.2% |
| Total income | 186.97 | 129.46 | +44.4% | 278.78 | −32.9% |
| Profit before tax | 15.29 | 17.42 | −12.2% | 58.28 | −73.8% |
| Net profit for the period | 11.39 | 12.97 | −12.2% | 43.04 | −73.5% |
| EPS, basic (₹) | 5.81 | 6.62 | −12.3% | 21.97 | −73.6% |
| Net margin (%) | 6.2 | 10.1 | 15.8 |
Consolidated
- Filed with BSE
- 26 Jul 2022, 13:17 IST
- Board meeting
- 25 Jul 2022
- Period
- 01 Apr 2022 to 30 Jun 2022
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 26 Jul 2022, 13:17 IST
- Board meeting
- 25 Jul 2022
- Period
- 01 Apr 2022 to 30 Jun 2022
- Review status
- Unaudited
- Source
- XBRL filing on BSE